-
EP4110362
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4110362
| EP4110362 - COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 02.12.2022 Database last updated on 22.08.2024 | |
| Former | The international publication has been made Status updated on 03.09.2021 | ||
| Former | unknown Status updated on 30.03.2021 | Most recent event Tooltip | 05.04.2024 | New entry: Additional fee for renewal fee: despatch of communication + time limit | Applicant(s) | For all designated states Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, MA 02139 / US | [2023/01] | Inventor(s) | 01 /
EPSTEIN, David C/o Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, MA 02139 / US | 02 /
MCHALE, Duncan C/o Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, MA 02139 / US | [2023/01] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/01] | Application number, filing date | 21713516.9 | 26.02.2021 | [2023/01] | WO2021US19968 | Priority number, date | US202062981867P | 26.02.2020 Original published format: US 202062981867 P | US202062983091P | 28.02.2020 Original published format: US 202062983091 P | US202063000201P | 26.03.2020 Original published format: US 202063000201 P | US202063021224P | 07.05.2020 Original published format: US 202063021224 P | US202063053916P | 20.07.2020 Original published format: US 202063053916 P | US202063074429P | 03.09.2020 Original published format: US 202063074429 P | [2023/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021174041 | Date: | 02.09.2021 | Language: | EN | [2021/35] | Type: | A1 Application with search report | No.: | EP4110362 | Date: | 04.01.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.09.2021 takes the place of the publication of the European patent application. | [2023/01] | Search report(s) | International search report - published on: | EP | 02.09.2021 | Classification | IPC: | A61K35/741, A61P17/06, A61P31/14, A61K31/573 | [2023/01] | CPC: |
A61K35/741 (EP,KR,US);
A61K31/196 (US);
A61K31/215 (US);
A61K31/351 (US);
A61K31/4706 (US);
A61K31/53 (US);
A61K31/573 (EP);
A61K31/675 (US);
A61K31/7056 (US);
A61K38/21 (US);
A61K39/3955 (US);
A61K45/06 (EP,KR,US);
A61K9/0053 (US);
A61K9/2009 (US);
A61K9/2013 (US);
A61K9/2018 (US);
A61K9/2027 (US);
A61K9/2054 (US);
A61K9/2813 (US);
A61K9/2846 (US);
A61K9/2853 (EP);
A61K9/485 (US);
A61K9/4858 (EP,US);
A61K9/4891 (EP);
A61P11/00 (EP,US);
A61P17/06 (EP);
A61P31/14 (EP,KR,US);
A61P37/06 (US);
G01N33/56983 (EP);
G01N33/6869 (EP);
A61K2300/00 (KR);
G01N2333/11 (EP);
G01N2333/135 (EP);
G01N2333/165 (EP);
G01N2333/5255 (EP);
G01N2333/5412 (EP);
| C-Set: |
A61K31/573, A61K2300/00 (EP);
A61K35/741, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/01] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR REDUZIERUNG DER CYTOKINEXPRESSION | [2023/01] | English: | COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION | [2023/01] | French: | COMPOSITIONS ET MÉTHODES POUR RÉDUIRE L'EXPRESSION DES CYTOKINES | [2023/01] | Entry into regional phase | 22.09.2022 | National basic fee paid | 22.09.2022 | Designation fee(s) paid | 22.09.2022 | Examination fee paid | Examination procedure | 22.09.2022 | Examination requested [2023/01] | 22.09.2022 | Date on which the examining division has become responsible | 27.04.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.07.2023 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 28.02.2023 | 03 M06 Fee paid on 13.07.2023 | 29.02.2024 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2011053653 (MAYO FOUNDATION [US], et al) [X] 1,4 * figure 7; claim 12 * [I] 5-25; | [IP]WO2021026130 (EVELO BIOSCIENCES INC [US]) [IP] 1,4-25 * paragraphs [0001] - [0021]; figures 1,13C *; | [XI] - ERIC V. MARIETTA ET AL, "Suppression of Inflammatory Arthritis by Human Gut-Derived Prevotella histicola in Humanized Mice : SUPPRESSION OF INFLAMMATORY ARTHRITIS BY PREVOTELLA HISTICOLA", ARTHRITIS & RHEUMATOLOGY (HOBOKEN), US, (20161128), vol. 68, no. 12, doi:10.1002/art.39785, ISSN 2326-5191, pages 2878 - 2888, XP055665204 [X] 1,4 * figures 1,4A * [I] 5-25 DOI: http://dx.doi.org/10.1002/art.39785 | [IP] - Anonymous, "Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases", (20200302), URL: https://ir.evelobio.com/node/7126/pdf, (20210531), XP055809218 [IP] 1,4-25 * page 1, paragraphs 4,6 * | [A] - Anonymous, "Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial", (20191105), URL: https://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-reports-further-positive-edp1815-interim, (20210531), XP055808926 [A] 1,4-25 * the whole document * | by applicant | US2019099458 | - CABALLERO et al., "Cooperating Commensals Restore Colonization Resistance to Vancomycin-Resistant Enterococcus faecium", Cell Host & Microbe, (20170000), vol. 21, pages 592 - 602 | - HADJADJ et al., Science, (20200000), vol. 369, pages 718 - 724 | - GALANI et al., Nature Immunology, (20210000), vol. 22, pages 32 - 40 | - ZHENG et al., Signal Transduction and Targeted Therapy, (20200000), vol. 5, page 299 | - YEOH et al., Gut, (20210000), vol. 0, pages 1 - 9 | - MOORE et al., Science, (20200501), vol. 368, no. 6490, pages 473 - 474 | - SHIMABUKURO-VORNHAGEN et al., Journal for ImmunoTherapy of Cancer, (20180000), vol. 6, page 56 | - FINE JPGRAY RJ, "A Proportional Hazards Model for the Subdistribution of a Competing Risk", J Amer Stat Assn, (19990000), vol. 94, no. 446, pages 496 - 509 | - GRALINSKI LEBARIC RS, "Molecular pathology of emerging coronavirus infections", J Pathol, (20150000), vol. 235, pages 185 - 195 | - GUAN WJNI ZYHU Y et al., "Clinical Characteristics of Coronavirus Disease 2019 in China", NEJM, (20200000), vol. 382, no. 18, pages 1708 - 1720 | - HAGAU NSLAVCOVICI AGONGANAU DN et al., "Clinical aspects and cytokine response in severe H1N1 influenza A virus infection", Crit Care, (20100000), vol. 14, no. 6, doi:10.1186/cc9324, page R203, XP021091679 DOI: http://dx.doi.org/10.1186/cc9324 | - HUANG CWANG YLI X et al., "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, (20200000), vol. 395, no. 10223, doi:10.1016/S0140-6736(20)30183-5, pages 497 - 506, XP086050317 DOI: http://dx.doi.org/10.1016/S0140-6736(20)30183-5 | - DE JONG MDSIMMONS CPTHANH TT et al., "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia", Nat Med, (20061000), vol. 12, no. 10, doi:10.1038/nm1477, pages 1203 - 7, XP009162079 DOI: http://dx.doi.org/10.1038/nm1477 | - MAHARAJ R, "King's Critical Care - Evidence Summary Clinical Management of COVID-19", King's Critical Care, (20200309), pages 1 - 24 | - LIU YYANG YZHANG C et al., "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury", Sci. China Life Sci., (20200000), vol. 63, pages 364 - 374 | - MEHTA PMCAULEY DFBROWN M et al., "Covid-19: consider cytokine storm syndromes and immunosuppression", The Lancet, (20200000), vol. 395, doi:10.1016/S0140-6736(20)30628-0, pages 1033 - 4, XP086105444 DOI: http://dx.doi.org/10.1016/S0140-6736(20)30628-0 | - PEIRIS JSCHU CMCHENG VC et al., "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study", Lancet, (20030000), vol. 361, doi:10.1016/S0140-6736(03)13412-5, pages 1767 - 72, XP004783472 DOI: http://dx.doi.org/10.1016/S0140-6736(03)13412-5 | - VILLAR JPEREZ-MENDEZ LBLANCO J et al., "Spanish Initiative for Epidemiology, Stratification, and Therapies for ARDS (SIESTA) Network. A universal definition of ARDS: the Pa02/Fi02 ratio under a standard ventilatory setting--a prospective, multicenter validation study", Intensive Care Med, (20130400), vol. 39, no. 4, pages 583 - 92 | - WANG DHU BHU C et al., "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China", JAMA, (20200000), vol. 323, pages 1061 - 1069 | - WONG CKLAM CWKWU AKL et al., "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome", Clin Exp Immunol, (20040000), vol. 136, doi:10.1111/j.1365-2249.2004.02415.x, pages 95 - 103, XP003004986 DOI: http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x |